Sai Life Sciences IPO subscription starts on 11 December 2024 and will close on 13 December 2024. The company plans to raise around INR 3,042.62 crores via the IPO. The price band is fixed at INR 522 – 549 per share. Sai Life Sciences IPO market lot has 27 shares, and the minimum application amount is INR 14,823. The retail quota is 35%, QIB is 50%, and NII is 15%.
Check Sai Life Sciences IPO Subscription Status here. The subscription figures are taken from BSE and NSE and are updated at regular intervals. Here you can find Sai Life Sciences IPO Subscription Status segregated by days and investor categories.
Sai Life Sciences IPO Subscription Status – Live Updates
Coming soon
Shares allotted to anchor investors are not included in these calculations. Similarly, shares allotted to market makers, if any, are not part of these calculations.
Read Also: Last Day Cut Off Time In ASBA: Ensure Timely IPO Applications
Sai Life Sciences – Business Background
Sai Life Sciences is a prominent Contract Research, Development, and Manufacturing Organization (CRDMO) that specializes in supporting innovative pharmaceutical and biotechnology companies. Founded in 1999, the company has established itself as a key player in the global pharmaceutical landscape, focusing on the discovery, development, and manufacturing of complex small molecules. With a vision to launch 25 new medicines by 2025, Sai Life Sciences collaborates with over 280 pharmaceutical innovators, including 18 of the top 25 global pharma companies. Its operations span across regulated markets such as the United States, Europe, and Japan, leveraging its dual expertise in contract research and contract development and manufacturing.
In FY 2024, Sai Life Sciences reported significant financial growth, achieving a revenue of INR 1,494.27 crore and a net profit of INR 82.81 crore. The company’s EBITDA margin stood at 20.48%, reflecting its efficient operational model and commitment to quality service delivery. The firm has consistently demonstrated robust performance with a compound annual growth rate (CAGR) of approximately 29% over the past three years. This growth trajectory is supported by strategic investments in research and development facilities in key innovation hubs such as Cambridge, USA, and Manchester, UK, alongside cost-effective manufacturing capabilities in India.
Read Also:Â Vishal Mega Mart IPO Analysis
Investor Categories in Sai Life Sciences IPO Subscription
The three most important categories of IPO investors defined by SEBI are part of Sai Life Sciences IPO.
Qualified Institutional Buyers (QIB) – Examples of QIBs are Foreign Portfolio Investors (FPIs), Scheduled Commercial Banks, Mutual Funds, Venture Capital Funds, Foreign Venture Capital Investors (FVCIs), Alternative Investment Funds (AIFs), Insurance Companies, Provident Funds and Pension Funds with a minimum corpus of INR 250 million.
Generally, 50% of the offer is reserved for QIBs. Some of these are classified as anchor investors which work towards stabilizing an IPO.
Non-Institutional Investor (NII) – These are affluent investors who can invest more than INR 200,000. In other words, these are High Networth Individuals (HNIs). Generally, 15% of the offer is reserved for this category. Bids in the category need to exceed INR 200,000. Typical examples include Category III FPIs, resident Indian individuals, HUFs (in the name of Karta), companies, corporate bodies, eligible NRIs, scientific institutions, societies, and trusts.
The NII category is further divided into two – big and small – the threshold application amount being INR 10,00,000 (INR 10 lakh).
Retail Individual Investor (RII) – This category is purely meant for small investors, whose bid must not exceed INR 200,000 per person. Usually, 35% of total shares are reserved for this category in the case of a company with profitable operations. If the IPO-bound company does not fulfill this criterion, only 10% of shares are reserved for retail investors.Â
Employee – Shares reserved for company employees are not part of the Net Offer and there may additionally be a discount on offer price to encourage employees to subscribe. Investors in the employee category may also apply under the retail category in an IPO. Therefore, this category of IPO investors has a unique advantage.
Read Also:Â Top 10 CEO Salary in India
Sai Life Sciences IPO Subscription Status FAQs
When will the Sai Life Sciences IPO subscription start?
Sai Life Sciences IPO subscription starts on 11 December and ends on 13 December 2024.
How to subscribe to Sai Life Sciences IPO?
You can subscribe to the IPO through ASBA and non-ASBA options. To use ASBA, login to your bank account and apply for the IPO online. Alternatively, you can download the form online or obtain a physical form, then submit the completed form to your broker or bank.
When will Sai Life Sciences IPO be listed?
Sai Life Sciences IPO will be listed on 18 December 2024, on the BSE and NSE stock exchanges.
